Top news story of the day:

 

NeuShen Therapeutics closes Pre-A financing worth $ 20M

 

NeuShen Therapeutics announced the closure of a $20 million Series pre-A financing round led by LAPAM capital. The new funds will be used to expand its team and catalyze in-house CNS drug discovery in the U.S. and China.

 

NeuShen is a biotechnology company focusing on innovative drug research and development to address CNS disorders, applying dual research platforms, including AAV-based gene therapy and small molecule discovery.

 

“The successful completion of this fundraising jumpstarts our discovery engine to build a pipeline with AAV-based gene therapy and small molecule programs,” said Joan Shen, NeuShen’s founder and CEO. “CNS disease is an area with huge unmet needs. In the past few months, we have developed an achievable R&D strategy and built-up a substantial core team. In addition, multiple collaborations and partnerships have been discussed and established.”

 

Before founding NeuShen, Joan Shen served as head of R&D and CEO of I-Mab Biopharma. During her tenure, I-Mab was listed on Nasdaq and formed a global collaboration with AbbVie for CD-47 compound, lemzoparlimab. Prior to I-Mab, Joan was the head of development of Janssen Pharmaceutical Company of J&J China, where she led to multiple successful NDA/BLA approvals by China NMPA.

 

 

In other news:

 

MabPlex, a CDMO focused on biologics, filed an application for listing on the Shenzhen Stock Exchange to raise RMB 1.6 billion ($225.34 million).

 

By Sarina Yang